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Abstract
Modelling suggests hepatitis C virus (HCV) elimination is possible among men who 
have sex with men (MSM), with key screening groups including HIV- diagnosed MSM 
and MSM using pre- exposure prophylaxis (PrEP). Mathematical modelling was used 
to determine the cost- effectiveness of HCV case- finding strategies among MSM from 
the provider perspective, and to determine which interventions could achieve a 90% 
reduction in HCV incidence over 2015– 2030. At baseline, we assumed symptomatic 
screening in HIV- negative MSM (including PrEP users) and 12- monthly screening among 
HIV- diagnosed MSM. Improved case- finding strategies included screening alongside 
HIV testing in HIV- negative MSM not using PrEP (PrEP non- users); 12/6/3- monthly 
screening in PrEP users; and 6- monthly screening in HIV- diagnosed MSM, with the 
cost- effectiveness being compared incrementally. Costs (GBP) and quality- adjusted 
life years (QALYs) were assessed to estimate the mean incremental cost- effectiveness 
ratio (ICER) with a time horizon to 2050, compared to a willingness- to- pay threshold 
of £20,000/QALY. From the baseline, the most incrementally cost- effective strategy 
is to firstly undertake: (1) 12- monthly HCV screening of PrEP users (gaining 6715 
QALYs with ICER £1760/QALY), followed by (2) HCV screening among PrEP non- users 
alongside HIV testing (gaining 7048 QALYs with ICER £4972/QALY). Compared to the 
baseline, this combined strategy would cost £46.9 (95%CrI £25.3– £66.9) million and 
achieve the HCV elimination target in 100% of model runs. Additional screening in-
curs ICERs >£20,000/QALY compared to this combined strategy. In conclusion, HCV 
elimination can be achieved cost- effectively among UK MSM. Policymakers should 
consider scaling- up HCV screening in HIV- negative MSM, especially PrEP users, for 
achieving this target.
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1  |  INTRODUC TION
The last 10 years have seen a global epidemic of hepatitis C virus 
(HCV) among men who have sex with men (MSM), with the prev-
alence of HCV estimated at 1.5% in HIV- negative MSM and 6.3% 
among HIV- infected MSM.1,2 Although HCV is a lifelong chronic in-
fection, the development of direct- acting antiviral (DAA) treatments 
for HCV allow for successful treatment, with cure rates over 90% 
even among HIV co- infected individuals.3,4 This has led to the World 
Health Organization (WHO) developing a Global Health Sector 
Strategy to eliminate hepatitis as a public health threat by 2030; set-
ting targets to reduce the incidence of new chronic hepatitis B and 
C infections by 90% and the mortality attributable to hepatitis B and 
C by 65%.5
Existing initiatives to increase HCV screening and treatment 
among MSM in the UK and elsewhere have generally focussed on 
HIV- diagnosed MSM in contact with care because of their frequent 
health service contact,6 and their higher HCV incidence (~six-
fold higher in the UK than in HIV- negative MSM not using PrEP).1 
However, significant HCV infection resides in HIV- negative MSM 
(1.2% prevalence in UK in 2008/2009),7 especially among those on 
HIV pre- exposure prophylaxis (2.1% in PROUD study).8 Although 
three recent European studies have demonstrated scaling- up HCV 
treatment can result in substantial reductions (51%– 77%) in HCV 
incidence among HIV- positive MSM,6,9,10 our modelling suggests 
that screening and treatment is also needed in HIV- negative MSM to 
reach the HCV elimination targets among all MSM.11
The coverage of HIV testing and treatment among MSM has 
improved over the last decade in the UK, with 92% of people liv-
ing with HIV being diagnosed in 2017, and the proportion of diag-
nosed individuals accessing ART increasing from 85% to 98% over 
2012– 2017.12 PrEP has also become readily available in Wales and 
Scotland,13 and is being rolled out in England.14 In this changing en-
vironment, our previous modelling suggested that numerous screen-
ing strategies could achieve HCV elimination among MSM without 
the need for behavioural change, with options including differing 
levels of screening among HIV- diagnosed MSM and HIV- negative 
MSM on or off PrEP.11 To help inform policy decisions for achieving 
HCV elimination, this analysis uses modelling to determine which 
of these HCV screening strategies is the most cost- effective for 
achieving HCV elimination among MSM in the UK.
2  |  METHODS
Throughout this work, we make use of the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) checklist.15
2.1  |  Model derivation
We adapt a previous deterministic continuous- time model of HIV 
and HCV transmission among all UK MSM11,16 to include stages for 
HCV- related liver disease progression and prior exposure to infec-
tion (full details and further parameter discussion in supplemen-
tary material Appendix S1). The model (Figure S1) stratifies MSM 
by compartments for HIV and PrEP status (susceptible on/off PrEP, 
acute HIV infection on/off PrEP, undiagnosed chronic HIV infection 
and diagnosed chronic HIV infection); HCV- status (susceptible with-
out HCV antibodies, susceptible with HCV antibodies, acute HCV- 
infection, undiagnosed and diagnosed chronic HCV- infection); stage 
of liver disease progression (undamaged, fibrosis stages F1 through 
to F4, decompensated cirrhosis, hepatocellular carcinoma (HCC), 
liver transplantation and post- liver transplantation) and either low- 
or high- risk sexual behaviour, defined by the number of anal sex 
partners (high- risk defined as ≥15/year). We assume no change in 
sexual risk over time.
Individuals enter the model at age 15, susceptible to HIV and 
HCV infection, and not using PrEP. HIV and HCV transmission occur 
at rates related to an individual's sexual risk and prevalence of HIV 
and HCV among their sexual partners. HCV infectivity is elevated 
for HIV- HCV co- infected individuals (by 2.6- fold).17 MSM mix assor-
tatively, more commonly choosing partners of the same sexual risk 
and HIV- status.
A proportion of MSM clear HCV spontaneously (lower 
proportion among HIV- positive MSM) returning to a state of 
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Globally, we face an epidemic of hepatitis C virus (HCV) among men who have sex with men 
(MSM). However, new direct- acting antivirals for HCV have cure rates over 90% (regardless 
of HIV co- infection). This has led to the World Health Organization (WHO) setting targets to 
reduce the incidence of new chronic HCV infections by 90% by 2030. We project that HCV 
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consider scaling- up HCV screening in HIV- negative MSM, especially PrEP users; with enhanced 
screening in both these groups necessary for achieving the WHO target. Plus, enhanced screen-
ing among HIV- diagnosed MSM is not as cost- effective.
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HCV susceptibility, with the remainder becoming chronically 
infected. Chronically infected MSM progress through liver 
disease states (Figure S1) with HCV disease- related death oc-
curring from the decompensated cirrhosis, hepatocellular car-
cinoma, liver transplant and post- liver transplant stages. HIV 
co- infection increases liver disease progression,18 although this 
is slowed with ART.19 We model this by assuming a weighted 
rate of progression within our HIV- diagnosed compartment, 
dependent on the proportion currently on ART. Following ef-
fective HCV treatment, we assume disease progression ceases 
if individuals are at fibrosis stage F3 or lower20,21 and is slowed 
among those with compensated cirrhosis (F4) or decompen-
sated cirrhosis,21,22 while continuing at the same rate for those 
with more progressed disease.
HIV- negative individuals may initiate using PrEP, which reduces 
their risk of HIV acquisition by 86%– 97%.23,24 PrEP was assumed to 
scale- up from 2018 to give a coverage of PrEP among HIV- negative 
MSM of 10%– 15% by 2020. We also explore a scenario where 
PrEP coverage reaches between 20% and 30%, as may occur in the 
UK.25 The proportion of high- risk and low- risk MSM on PrEP is de-
termined by the proportions who would be eligible based on NHS 
England criteria. The average duration spent on PrEP is assumed to 
be 13.9 months.26 PrEP users are screened 3- monthly for HIV and 
upon diagnosis stop using PrEP. This frequent HIV testing means 
PrEP users are diagnosed before reaching chronic HIV infection.27 In 
contrast, PrEP non- users who acquire HIV infection are assumed to 
remain undiagnosed until they reach chronic HIV infection because 
the current UK HIV testing rate is 2.3 years.28
The baseline model assumes HIV- negative MSM are diagnosed 
for HCV based upon symptomatic presentation after 5– 15 years. In 
contrast, undiagnosed HIV- positive MSM receive HCV testing only 
following HIV- diagnosis and HIV- diagnosed MSM are assumed to 
screen annually in line with UK guidelines and testing behaviour 
at UK HIV clinics.6,29,30 Pre- 2018, we assume 2.2 years from HCV 
diagnosis to completing HCV treatment, consistent with UK data 
for pre- DAA treatments,29 with this decreasing to six months from 
2018 in line with more recent estimates.6 Before 2015, we assume 
different HCV sustained viral response (SVR) rates for HIV- positive 
(SVR of 35%– 42%)31 and HIV- negative MSM (SVR of 59%– 69%)32 
based on pre- DAA treatments, but then assume higher cure rates 
from 2015 for DAA therapies (SVR of 90%– 100%),29 with MSM 
failing treatment being retreated at the same rate as initial HCV 
treatment.
2.2  |  Cost estimations and health utilities
For this analysis, we take the perspective of the UK National Health 
Service. We assumed UK MSM to number between 650,000– 
750,000 based on estimates from Natsal33 and UK data from the 
European MSM Internet Survey (EMIS- 2010).34 The costs of HCV 
care for different stages of HCV- related disease were adapted 
from previously published estimates for the UK (Table 1).35– 37 We 
broadly split these costs into three categories, which we inflate to 
2020/21 prices using the hospital and community health services 
index. The first category comprises the ongoing healthcare costs as-
sociated with HCV- infection prior to liver transplants.35 The second 
category comprises the cost of a liver transplantation, including the 
procedural cost and subsequent cost of the patient after a success-
ful transplantation.36 The final category is the actual cost of a HCV 
treatment course at £10,000, which aligns with the NHS’s negoti-
ated drug price, alongside 12 weeks of treatment and SVR moni-
toring. Health utilities (quality- adjusted life years [QALYs]) and HCV 
disease progression rates came from previous studies.19,22,35– 39 For 
both QALYs and costs, we apply a discount rate of 3.5% per year 
from 2020 as recommended by the National Institute for Health and 
Clinical Excellence (NICE).40 Health utilities and costs for HIV were 
not included.
We also consider the intervention costs of HCV screening. We 
assume that HCV antibody testing is performed on all screened 
MSM,37,41 with reflex RNA testing occurring if they test antibody 
positive.37,41 We assume these tests are done using blood samples 
already taken during routine PrEP/HIV/sexual health check- ups. 
This means the cost for each HCV test only includes lab testing, plus 
an assumed 5 min of specialist nurse time for HCV- related discus-
sions around testing.37 For each positive HCV RNA test, we assume 
costs for pre- treatment care including ten minutes of phlebotomist 
and consultant time, and the costs of diagnostics for full blood 
count, liver function, HCV viral load and genotyping, fibroscan and 
ultrasound.37
2.3  |  Parameterization of sexual risk behaviour
Sexual behaviours were parameterized using data from UK- based 
respondents to EMIS- 2010, an online survey about HIV/STI- related 
morbidities, behaviours, needs and interventions among MSM 
across Europe.42 Over 180,000 men from 38 countries completed 
the survey, including 18,000 from the UK. From EMIS- 2010, we 
calculated key behavioural parameters given in Table S5 and sum-
marized in Table 1. Briefly, EMIS- 2010 data suggest 17.4% of UK 
MSM are high- risk (≥15 partners), among whom the prevalence of 
chemsex in the last year is higher than among low- risk MSM (22.6% 
vs. 11.5%). Chemsex adds an additional risk factor for HCV and HIV 
infection among the high- risk group above and beyond having more 
sexual partners.43,44 The model assumes that MSM have sex more 
often with others of the same perceived HIV- status, with perceived 
HIV- positive concordant partnerships having lower condom use 
(13%) than other partnerships (68%).
2.4  |  Model calibration
Assuming historic levels of HCV screening and pre- DAA SVR rates 
with no PrEP, the model was firstly calibrated to give a stable HIV 
and HCV epidemic in 2012. This is in line with HCV incidence 
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TA B L E  1  Key model parameters with ranges and details of estimation included
Model parameters
Value and uncertainty 
rangea  Ref Comment
HCV- related parameters
Efficacy of HCV treatment with 
DAAs— after 2015
95% (90%– 100%) 3,4 Efficacy is equivalent to the proportion of MSM 
achieving sustained viral response
Average delay from HCV diagnosis 
to completion of treatment 
before 2018.
2.2 years 6,29 UK CHIC data for HIV- diagnosed MSM and assume 
same for other MSM
Average delay from HCV diagnosis 
to completion of treatment after 
2018.
0.5 years 6 Duration of DAA treatment generally 8– 12 weeks, 
with an assumed 3– 4 months waiting period 
based on time to treatment of 3.7 months in HIV- 
diagnosed MSM in London.
Behavioural parameters
Proportion of MSM that are low risk 0.83 (0.79– 0.86) EMIS−2010 Proportion of MSM with <15 anal sex partners in the 
last year. Proportion who are high risk is simply 
the remaining proportion of the population.
Number of anal sex partners in each year
Low- risk 2.9 (2.3– 3.5) EMIS−2010 Average number of anal sex partners in each group 
with a ±20% uncertainty range added to each.High- risk 29.1 (23.3– 34.9)
Additional relative risk of HCV and 
HIV acquisition among high- risk 
MSM compared to low- risk 
MSM (based on chemsex 
participation in last year)
HIV: 1.3 (1.1– 1.5)
HCV: 1.5 (1.1– 1.9)
EMIS−201043,44 EMIS−2010 data on prevalence of chemsex in last 
year for low- and high- risk MSM combined 
with estimated increased risk of HIV and HCV 
acquisition due to chemsex in MSM studies. 
Relative risk is difference between low- and high- 
risk MSM.51
The proportion of MSM who mix 
like with like by HIV- status
0.35 (0.28 −0.42) EMIS−2010 EMIS−2010 data on proportion of partnerships 
chosen between people of the same HIV- status 
assuming no errors in judgement.
Probability of condom usage 
between HIV- diagnosed MSM 
and a partner assumed to be 
HIV- positive
13.0% (10.4%– 15.6%) EMIS−2010 EMIS−2010 data on condom use with last casual 
partner when both sides of partnership are 
thought to be HIV- positive. Assume range ±20% 
either side.
Probability of condom usage in other 
MSM partnerships (not ones 
thought to be both HIV- positive)
68.0% (54.4%– 81.6%) EMIS−2010 EMIS−2010 data on condom use with last casual 
partner when partnerships not thought to be 
sero- concordant. Assume range ±20% either side.
PrEP- related parameters
Proportion of HIV- negative MSM 
taking up PrEP by 2020
10%– 15% EMIS−2010 Based on EMIS−2010 eligibility estimates
Relative increase in coverage of 
PrEP in high- risk MSM versus 
low- risk MSM
2.6 (2.4– 2.8) EMIS−201027 EMIS−2010 data applied to NHS England eligibility 
criteria for low- and high- risk MSM
Efficacy of PrEP in reducing HIV 
incidence
91.5% (86.0%– 97.0%) 23,24 Range in efficacy from UK PROUD study23 and real- 
world study of PrEP use among MSM in France 
and Canada.24
Screening assumptions
Rate of HIV testing for PrEP users Every 3 months 23 Standard of care for HIV testing in PrEP users in UK
Time between HIV tests for PrEP 
non- users
2.3 (1.2– 3.5) years 28 Starting in the model from 2017. Previous to this, we 
use the range 3.2 (2.6−3.8).
Time until HCV diagnosis for PrEP 
users (baseline)
10 (5– 15) years 52 HIV- negative MSM not normally diagnosed with 
HCV until have symptoms unless they are high 
risk, assumed as 10 (5– 15) years. Varied in the 
model when looking at other scenarios.
Time until HCV diagnosis for PrEP 
non- users (baseline)
10 (5– 15) years 52
(Continues)
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data among HIV- diagnosed MSM from the UK Collaborative HIV 
Cohort (UK CHIC) study (although cumulative prevalence of HCV 
increased slightly from 9.5% to 9.9% in this group from 2009 to 
2011)29,45; a research collaboration among UK centres providing 
HIV clinical care.2
To calibrate the model, we randomly sampled 1000 model pa-
rameter sets from their uncertainty distributions given in Tables S3 
and S5. For each parameter set, we used the Levenberg- Marquardt 
algorithm to perform non- linear least- squares fitting to estimate 
transmission parameters for HIV and HCV that resulted in each 
model run at equilibrium (assumed to be 2012) giving an overall HIV 
prevalence within the range 4.3%– 5.3% and chronic HCV prevalence 
among HIV- infected MSM within the range 9.6%– 10.2% (see Figures 
S3– S7 for further details).29 Although not fit to the chronic preva-
lence of HCV among HIV- negative MSM, over 95% of the resulting 
runs projected a prevalence within the 95% confidence interval of 
the estimated HCV prevalence (0.6%– 2.1%) among HIV- negative 
MSM from a UK study.7 As shown in our previous paper, our result-
ing model projections for HCV incidence among HIV- diagnosed and 
HIV- negative MSM compare well with UK data from the pre- DAA 
period. All our results use the 95% credibility interval (95%CrI) esti-
mated from our 1000 model fits.
For each model fit, we assume that over 2012– 2017 there is 
an increase in (1) proportion of HIV- diagnosed MSM on ART from 
85%46 to 98%12; (2) proportion of those on ART that are virally sup-
pressed from 72% to 97%; and (3) HIV testing frequency from every 
3.2 years45 to 2.3 years.28 As in our previous paper,11 the relative 
decline in HIV incidence from our model projections was validated 
against available UK data, which indicates a 55.5% decrease in the 
number of annual HIV infections in 2017 compared to 2012.12 HCV 
prevalence and incidence also decrease over this period due to the 
switch to DAA treatments.3,4 After 2017, we retain parameters at 
these values except for introducing PrEP in 2018, with the uptake 
rate fitted to achieve a stable coverage of 10– 15% among all HIV- 
negative MSM by 2020.
2.5  |  Model analyses
We firstly determined the best- value- strategy to implement 
from 2020, defined as the combination of case- finding interven-
tions which has the highest impact (measured in QALYs gained), 
while remaining incrementally cost- effective (defined as having a 
mean incremental cost- effectiveness ratio (ICER) of ≤£20,000/
QALY) compared to the next best alternative using a time ho-
rizon of 30 years from 2020. Modelled strategies included all 
combinations of the following: (1) HIV- diagnosed MSM being 
screened every 12 (baseline) or 6 months; (2) PrEP users being 
screened symptomatically (after 5– 15 years; baseline), or every 
12, 6 or 3 months; and (3) HIV- negative MSM not on PrEP (PrEP 
non- users) being screened symptomatically (baseline) or con-
comitantly with intermittent HIV screening (assumed on average 
every 2.3 years).28 The mean cost and impact in QALYs for each 
intervention combination were plotted to identify the efficiency 
frontier, which joins the incrementally most cost- effective inter-
ventions as resources increase. This frontier determines the opti-
mal order in which interventions should be implemented and was 
used to identify the best- value- strategy with highest impact that 
was still cost- effective compared to the previously chosen option 
on the frontier.
Model parameters
Value and uncertainty 
rangea  Ref Comment
Frequency of HCV testing in HIV- 
diagnosed MSM (baseline)
Annual 6,29,30 In line with 2017, BASHH guidelines and rates 
observed in some clinics. Varied in modelled HCV 
screening scenarios.
HCV- related costs
HCV DAAs (per treatment) £10,000.00 Constant price of HCV DAAs assumed when 
sampling parameters.
HCV Antibody test £10.22b  37 Uniform range around the mean (±20%). New patient 
engagement includes 10 min of phlebotomist 
and consultant time, and the costs of diagnostics 
for full blood count, liver function, HCV viral 
load and genotyping, fibroscan and ultrasound. 
Treatment and SVR monitoring including full 
blood counts, liver function tests and HCV 
viral load tests. Requiring specialist nurse and 
phlebotomist time.
HCV RNA test £45.57b  37
Hourly rate of pay for specialist 
nurse (assumed use of time per 
test is 5 min)
£15.72b  37
New patient engagement £325.84b  37
12 weeks treatment monitoring £385.04b  37
SVR monitoring £154.02b  37
(For the extended version see Table S5).
Abbreviations: HCV, hepatitis C; MSM, men who have sex with men; DAA, direct- acting antiviral; SVR, sustained virologic response.
a Some parameters given with a point estimate only.; b Estimates from 2018/2019, but these are inflated in our model to prices for 2020/21 using the 
Hospital and Community Health Services Pay and Price Index Inflation until 2016/2017 when it was discontinued, with UK inflation rates used for 
time points beyond this.
TABLE 1 (Continued)
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Secondly, we estimated the proportion of model runs in which 
the best- value- strategy is projected to reach the elimination target 
of decreasing HCV incidence by 90% by 2030 compared to 2015 
levels. If this option did not reach the elimination target, we then 
assessed what additional screening was required (incrementally be-
yond the £20,000/QALY threshold) to ensure over 95% of model 
runs achieved the elimination target. The intervention meeting this 
additional criterion is defined as our optimal- elimination- strategy.
2.6  |  Sensitivity analyses
To ascertain which parameters are important for determining vari-
ability in our cost- effectiveness projections, we performed a linear 
regression analysis of covariance (ANCOVA) on all model runs of the 
optimal- elimination- strategy, looking separately at QALYs gained 
and costs incurred. The proportion of the sum of squares contrib-
uted by each parameter was calculated to determine each param-
eters’ importance to the variability in our projections.
We also performed one- way sensitivity analyses on the pro-
jected relative reduction in HCV incidence from 2015 to 2030 and 
the cost/QALY for the optimal- elimination- strategy compared to 
the baseline where we varied the following: (1) 4 versus 6 months 
between HCV diagnosis and treatment completion; (2) condom use 
among PrEP users and their partners halves from 64% to 32%; (3) 
PrEP is distributed evenly between high and low- risk MSM, or (4) to 
just high- risk MSM; (5) no increased infectiousness of HCV with HIV 
co- infection; (6) high (4.4- fold) increased infectiousness of HCV with 
HIV- coinfection (7) less HIV ‘serosorting’, modelled as 50% less like- 
with- like mixing based on HIV- status; (8) a decreased time horizon of 
10 years (instead of 30 years); (9) a declining or (10) increasing HCV 
epidemic (instead of stable), modelled as a 20% decrease/increase 
in the force of infection for HCV after reaching equilibrium in 2012; 
(11) halving the cost of HCV treatment from £10,000 to £5000; (12) 
no discounting of costs and QALYs; and (13) doubled PrEP coverage, 
reaching 20%– 30% instead of 10%– 15% by 2020. Within these sce-
narios, we also make the equivalent changes to the baseline scenario 
when making the new projections. For the doubled PrEP coverage 
scenario, we also determined if the optimal- elimination- strategy 
changes.
3  |  RESULTS
3.1  |  Main analyses
Compared to the baseline scenario, our model projections in Figure 1 
show that improving screening in HIV- negative MSM on or off PrEP 
will result in considerable additional impact on HCV incidence or 
QALYs gained over 2020– 2050. For instance, solely improving 
screening among PrEP users to every 12 months will result in 6715 
(95%CrI 2257– 14,050) QALYs gained while screening PrEP non- users 
alongside their HIV testing will gain 10,749 (95%CrI 3548– 22,619) 
QALYs. Conversely, little impact is achieved from improving screen-
ing among HIV- diagnosed MSM or further increasing screening in 
PrEP users, with 6- monthly screening of PrEP users only gaining 719 
(95%CrI 77– 1460) further QALYs compared to 12- monthly screen-
ing, while screening HIV- diagnosed MSM 6- monthly only gaining 
495 (95%CrI 53– 991) QALYs compared to baseline. In terms of com-
bined scenarios, significant incremental impact is achieved from in-
creased HCV screening among both PrEP users and non- users, with 
12- monthly screening in PrEP users plus screening PrEP non- users 
alongside their HIV testing resulting in 13,763 (95%CrI 4973– 27,966) 
QALYs gained compared to baseline over 2020– 2050. In terms of 
TA B L E  2  Incremental costs and QALYs gained over 2020– 2050 for different HCV screening strategies
Optimal order of implementation of HCV case- finding 
strategies in UK MSM. Baseline PrEP users yearly
PrEP users screened yearly; 
HIV- negative non- PrEP users 
screened when HIV tested;
PrEP users screened yearly; HIV- negative 
non- PrEP users screened when HIV tested; 
HIV- diagnosed screened 6 monthly
PrEP users screened 6- monthly; HIV- negative 
non- PrEP users screened when HIV tested; HIV- 
diagnosed screened 6 monthly
PrEP users screened 3- monthly; HIV- 
negative non- PrEP users screened when 
HIV tested; HIV- diagnosed screened 6 
monthly
Scenario abbreviation - P12 P12, N P12, N, D D, N, P6 D, N, P3
Is elimination target reached between 2015 and 



















QALYs gained compared to previous scenario - 6715 (2257– 14,050) 7048 (2651– 13,892) 201 (137– 278) 334 (20– 689) 181 (44– 455)
Overall intervention incremental costs compared to 
previous scenario (millions £)
- 11.8 (−0.1– 21.6) 35.0 (21.8– 46.2) 5.8 (3.9– 7.8) 18.8 (13.8– 25.2) 41.5 (31.1– 54.8)
Mean ICER (£ per QALY gained) - 1,760 4,972 28,845 56,274 229,636
HCV screening incremental costs (millions £) - 21.5 (16.1– 28.1) 43.7 (35.2– 52.8) 9.0 (7.1– 10.9) 23.7 (17.7– 31.0) 47.5 (35.7– 62.2)
HCV treatment incremental costs (millions £) - −7.7 (−20.1– −1.6) −6.4 (−17.0– −2.1) −2.9 (−3.9– −2.2) −4.6 (−7.4– −2.4) −5.6 (−8.6– −3.3)
HCV healthcare incremental costs (millions £) - −2.0 (−4.8– −0.5) −2.6 (−6.5– −0.6) −0.2 (−0.3– −0.2) −0.3 (−0.6– −0.2) −0.4 (−0.6– −0.2)
With costs split into those related to (1) treatment for HCV, (2) health care for HCV- related liver disease and (3) HCV screening. All costs are 
projected over a time horizon of 30 years, from 2020 until 2050. Results shown alongside 95% credibility interval over 1000 model runs.
Abbreviations: HCV, hepatitis C; MSM, men who have sex with men; QALY, quality- adjusted life year; ICER, incremental cost- effectiveness ratio.
a HCV elimination is defined as over 95% of model runs resulting in a ≥90% decrease in HCV incidence over 2015 to 2030.
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TA B L E  2  Incremental costs and QALYs gained over 2020– 2050 for different HCV screening strategies
Optimal order of implementation of HCV case- finding 
strategies in UK MSM. Baseline PrEP users yearly
PrEP users screened yearly; 
HIV- negative non- PrEP users 
screened when HIV tested;
PrEP users screened yearly; HIV- negative 
non- PrEP users screened when HIV tested; 
HIV- diagnosed screened 6 monthly
PrEP users screened 6- monthly; HIV- negative 
non- PrEP users screened when HIV tested; HIV- 
diagnosed screened 6 monthly
PrEP users screened 3- monthly; HIV- 
negative non- PrEP users screened when 
HIV tested; HIV- diagnosed screened 6 
monthly
Scenario abbreviation - P12 P12, N P12, N, D D, N, P6 D, N, P3
Is elimination target reached between 2015 and 



















QALYs gained compared to previous scenario - 6715 (2257– 14,050) 7048 (2651– 13,892) 201 (137– 278) 334 (20– 689) 181 (44– 455)
Overall intervention incremental costs compared to 
previous scenario (millions £)
- 11.8 (−0.1– 21.6) 35.0 (21.8– 46.2) 5.8 (3.9– 7.8) 18.8 (13.8– 25.2) 41.5 (31.1– 54.8)
Mean ICER (£ per QALY gained) - 1,760 4,972 28,845 56,274 229,636
HCV screening incremental costs (millions £) - 21.5 (16.1– 28.1) 43.7 (35.2– 52.8) 9.0 (7.1– 10.9) 23.7 (17.7– 31.0) 47.5 (35.7– 62.2)
HCV treatment incremental costs (millions £) - −7.7 (−20.1– −1.6) −6.4 (−17.0– −2.1) −2.9 (−3.9– −2.2) −4.6 (−7.4– −2.4) −5.6 (−8.6– −3.3)
HCV healthcare incremental costs (millions £) - −2.0 (−4.8– −0.5) −2.6 (−6.5– −0.6) −0.2 (−0.3– −0.2) −0.3 (−0.6– −0.2) −0.4 (−0.6– −0.2)
With costs split into those related to (1) treatment for HCV, (2) health care for HCV- related liver disease and (3) HCV screening. All costs are 
projected over a time horizon of 30 years, from 2020 until 2050. Results shown alongside 95% credibility interval over 1000 model runs.
Abbreviations: HCV, hepatitis C; MSM, men who have sex with men; QALY, quality- adjusted life year; ICER, incremental cost- effectiveness ratio.
a HCV elimination is defined as over 95% of model runs resulting in a ≥90% decrease in HCV incidence over 2015 to 2030.
F I G U R E  1  Impact and costs of each different HCV screening strategies in MSM. (A) Cost and (B) QALYs gained by each HCV screening 
intervention compared with baseline HCV screening from 2020 to 2050. (C) Total decrease in HCV incidence between 2015 and 2030. Error 
bars represent the 95% credible interval over 1,000 simulations
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impact on incidence, all modelled scenarios reaching the elimination 
target included improved screening in HIV- negative MSM on and off 
PrEP (Table 2).
In terms of cost- effectiveness, our projections suggest (Figure 2) 
that starting from the baseline scenario our first priority should be 
to undertake the following: (1) 12- monthly screening among PrEP 
users (mean ICER £1760/QALY compared to baseline), then (2) HCV 
screening among HIV- negative PrEP non- users alongside their HIV 
testing (mean ICER £4972/QALY compared to (1)). In total, this com-
bined strategy would cost £46.9 (95%CrI £25.3– £66.9) million by 
2050, with a mean overall ICER of £3,405/QALY compared to the 
baseline. This combined intervention also reaches the HCV elimina-
tion target in 100% of runs, thus also being the optimal- elimination- 
strategy. Interestingly, HCV elimination cannot be achieved among 
all MSM (in over 95% of model runs) without combining case- finding 
strategies (1) and (2).
The next most cost- effective scenario is screening HIV- diagnosed 
MSM every 6 months. Although this strategy is cost- effective at 
an ICER of £10,090/QALY when just added to the baseline, it is 
not cost- effective when added to (1) and (2), gaining 201 (95%CrI 
137– 278) QALYs at a cost of £5.8 (95%CrI 3.9– 7.8) million, giving an 
ICER of £28,845/QALY.
3.2  |  Sensitivity analysis
Our ANCOVA analysis suggests the main contributors to variation 
in the projected QALYs gained for our optimal- elimination- strategy 
were as follows: the proportion of MSM who preferentially mix by 
risk- status (22.1% of variation) and HIV- status (6.9%); the probabil-
ity of condom use among MSM when at least one partner is HIV- 
negative (14.6%); and the efficacy of condoms in reducing HIV/HCV 
transmission (12.6%). For variation in the costs, the main contribu-
tors were as follows: the cost of HCV antibody testing (36.6%); the 
probability of condom use among MSM when at least one partner is 
HIV- negative (15.1%); and the efficacy of condoms in reducing HIV/
HCV transmission (11.1%).
Our univariate sensitivity analyses (Figure 3) indicate that the 
cost- effectiveness projections and the relative reduction in HCV in-
cidence by 2030 for the optimal- elimination- strategy were robust 
F I G U R E  2  Incremental QALYs gained 
and cost for HCV screening strategies 
compared to baseline HCV screening from 
2020 until 2050. Under an assumption 
of (A) 10%– 15% and (B) 20%– 30% PrEP 
coverage among HIV- negative MSM. 
Plotted points are mean values for 
each intervention combination from 
1000 parameter sets. The solid straight 
lines/frontiers join the mean values for 
the incrementally most cost- effective 
interventions as budget increases, with 
the associated mean ICER being shown 
(compared to the last intervention on the 
line). *HCV elimination is defined as a 
model run resulting in a ≥90% decrease in 
HCV incidence between 2015 and 2030. 
Dominant interventions along the frontier 
are labelled in bold
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to changes in the model assumptions. The greatest effect is seen 
for the scenario when health benefits and costs were only followed 
until 2030 instead of 2050. However, all model runs still projected 
that the optimal- elimination- strategy was cost- effective compared 
to the baseline scenario. Importantly, our model predicts that the in-
tervention will be more cost- effective in scenarios with higher HCV 
incidence.
Lastly, under the scenario of doubled PrEP coverage, the optimal- 
elimination- strategy remains the same, with a mean ICER of £3802/
QALY compared to the baseline scenario (Figure 2).
4  |  DISCUSSION
Our findings suggest that improving HCV case- finding and treatment 
among MSM in the UK is a cost- effective strategy for reaching HCV 
elimination without the need for additional risk reduction strategies. 
Existing PrEP, HIV care and sexual health appointments provide suf-
ficient opportunity to facilitate the required increase in screening, al-
though reductions to these services could affect the feasibility of these 
strategies. Our optimal- elimination- strategy adds to the current HCV 
screening guidance, indicating that 12- monthly testing among PrEP 
F I G U R E  3  One- way sensitivity analyses. (A) incremental cost per QALY gained (compared to baseline) and (B) the relative reduction in 
HCV incidence between 2015 and 2030 for the optimal- elimination- strategy under varied assumptions. Point and error bars represent the 
mean values and 95% central range of the model projections across 1,000 model fits. *These scenarios represent an increase (±20%) in the 
HCV transmission probability from 2012
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users and less frequently (around 2.3 years, alongside HIV testing) 
among PrEP non- users is most cost- effective (overall £3405/QALY). 
This strategy would gain 13,763 QALYS between 2020– 2050 and has 
an overall incremental cost of £46.9 million, including £43.7 million in 
additional screening costs compared to the baseline. Importantly, over 
a third of the added impact of the optimal strategy comes from screen-
ing current PrEP users, with just this and the improvement in screening 
of other HIV- negative MSM being sufficient to achieve elimination.
Although our projections were specific to the UK, our findings 
remained robust to numerous changes to our modelled assump-
tions. This included reductions in the cost of treatment (to £5000/
treatment course), assuming different HCV epidemic dynamics, 
incorporating reductions in condom use among PrEP users (risk 
compensation), different patterns of HIV- related mixing (serosort-
ing) and different eligibility criteria for initiating PrEP. This aids with 
the generalizability of our findings to other high- income settings. In 
the scenario of doubled PrEP coverage (20%– 30% of HIV- negative 
MSM), the costs and benefits of the optimal- elimination- strategy re-
main largely the same.
4.1  |  Comparison with literature
Other studies have estimated the cost- effectiveness of enhancing 
HCV screening in MSM. Firstly, two studies using models that do 
not account for dynamic HCV transmission showed it was cost- 
saving to undertake one- time screening among HIV- positive MSM in 
Germany,47 and cost- effective (<€10,000/QALY) to undertaken one- 
time or yearly screening among all MSM in Belgium.48 Otherwise, 
a dynamic transmission modelling analysis from Netherlands49 and 
another model analysis incorporating incidence and reinfection 
from the USA50 have shown it was cost- effective or cost- saving to 
undertake screening and/or treatment interventions among HIV- 
diagnosed MSM. Our study adds to these studies by using dynamic 
modelling to estimate the cost- effectiveness of undertaking screen-
ing among HIV- negative MSM stratified by PrEP usage, while also 
showing the importance of screening these groups for achieving 
HCV elimination among all MSM.
4.2  |  Strengths and limitations
We largely draw from the same strengths and limitations of our pre-
vious model.11 The strength of our analysis is in modelling the full 
co- epidemics of HIV and HCV among MSM in the UK, and using this 
model to determine optimal screening strategies among different 
MSM subgroups for achieving HCV elimination.
With regards to limitations, our model is not generalizable to 
all settings, especially low- /middle- income countries. However, 
given the robustness of our findings to many sensitivity analy-
ses, including different coverages of PrEP and variations in HCV 
epidemic dynamics, they should be generalizable to many high- 
income countries.
Secondly, simplifications were made when modelling the his-
toric HCV epidemic. As discussed in our previous paper, these in-
cluded assuming a stable HCV epidemic in 2012 (approximating 
incidence and prevalence data from that time),11 not explicitly in-
corporating the impacts of injecting drug use, and assuming MSM 
have constant numbers of anal sex partners over their lifetime. 
We also acknowledge that HCV screening occurs among HIV- 
negative MSM, but at frequencies that vary based on local testing 
procedures at sexual health services, country- level guidelines, and 
whether an individual accesses PrEP formally or informally. To by-
pass this complexity and give guidance on what HCV screening 
should occur among HIV- negative MSM, we assumed symptom-
atic screening at baseline. Similar variation is also likely in current 
HCV screening frequencies among HIV- diagnosed MSM, which 
we based on national guidance as it seems to capture what is hap-
pening in some HIV clinics.6 We also did not include health utilities 
or treatment costs associated with HIV infection, firstly because 
of an absence of explicit health utilities for HIV/HCV co- infection, 
and secondly for equity reasons. We do not think these factors 
should play a role in deciding whether HIV- infected MSM should 
be treated for HCV or not. Also, as DAA prices were confidential-
ity agreed with the NHS, we were unable to provide a reference 
to these costs. However, we believe these costs to be reflective 
of the actual price per treatment and have considered different 
prices in our sensitivity analyses. We also did not include the more 
limited access to liver transplants experienced by HIV- diagnosed 
MSM.
Lastly, uncertainty exists in the data used to parameterize and 
calibrate the model, resulting in uncertainty in our model projec-
tions. This includes uncertainty in sexual behaviour data obtained 
from the online EMIS- 2010 survey. Although EMIS- 2010 was 
self- selecting and so the data may be biased towards more sex-
ually active MSM,42 it is likely to be less biased than other much 
smaller surveys undertaken in gay venues or STI clinic settings. 
There is also uncertainty in the likely scale- up of PrEP across dif-
ferent UK regions, and the level of risk compensation that may 
occur among PrEP users. Encouragingly, incorporating risk com-
pensation improves the overall cost- effectiveness of our optimal 
strategy compared to the baseline scenario and does not affect 
whether this strategy achieves HCV elimination. Higher levels 
of PrEP coverage also resulted in a similar ICER and the same 
optimal- elimination- strategy.
5  |  CONCLUSIONS
Our findings have direct implications for any high- income country 
attempting to eliminate HCV among MSM. They strongly advocate 
for undertaking frequent HCV screening among HIV- negative MSM, 
especially among those on PrEP. This is currently not the focus of 
most HCV elimination initiatives occurring among MSM but is likely 
to be crucial for fully eliminating HCV among MSM. Fortunately, the 
screening costs for doing so are not large because additional HCV 
    |  11MACGREGOR Et Al.
testing can be incorporated within existing screening practices, with 
added testing and staff time costs being largely offset by reduced 
future costs in HCV care and treatment.
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